In Part 2, Dr. Matthay provides the rationale behind treating ARDS patients with MSC. Initial studies in a mouse model of ARDS, showed that treatment with MSCs increased levels of anti-inflammatory cytokines and antimicrobial peptides in the lung, and increased phagocytosis of bacteria by monocytes. Further studies in ex vivo perfused human lungs and in sheep with severe lung injury showed that treatment with MSCs improved oxygenation and reduced pulmonary edema. An NIH/NHLBI supported phase 1 clinical trial for safety has been completed and a randomized, blinded phase 2 trial has now been initiated to test the safety and efficacy of MSC treatment in human patients with ARDS.
View the full talk with additional resources on our website
The Acute Respiratory Distress Syndrome and Treatment with Mesenchymal Stem Cells
Carolyn Calfee explains how acute respiratory distress syndrome (ARDS) is a pulmonary edema, and Michael Matthay discusses treating ARDS patients with mesenchymal stem cells. (Talk recorded in November 2013)
- Part 1: Acute Respiratory Distress Syndrome: An OverviewAudience:
- Researcher
Duration: 11:18 - Part 2: Mesenchymal Stem Cell Therapy for ARDSAudience:
- Researcher
Duration: 34:52